Abstract Library

#2800 Thymosin Beta 4 Is an Autocrine Mitogen for Neuroendocrine Tumour Cells

Introduction: The most commonly used NET marker chromogranin A, has a sensitivity between 60-90% and a specificity of less than 50%, hence better NET markers are needed. Previous secretome analysis using BON1, NCI-H727 and SHP-77 cell lines has led to the discovery of various candidate NET markers. One such marker is Thymosin Beta 4 (TB4). TB4 is a small 43 amino acid intracellular peptide first isolated from bovine thymus tissue.TB4 or its oxidised form TB4SO are thought to play a role in various aspects of cancer biology including tumour invasion, metastasis and apoptosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Balasundaram P, Beaumont N, Liang S, Cuenco J, Lu X,

Keywords: neuroendocrine tumour, biomarkers, signalling,

#1856 Relationship Between Symptoms and HRQoL Benefits in Patients (pts) with Carcinoid Syndrome (CS): A Post-Hoc Analysis of Telotristat Ethyl (TE) TELESTAR Trial

Introduction: TELESTAR previously demonstrated the efficacy and safety of TE in pts with CS experiencing >4 Bowel Movements (BM) per day despite stable-dose somatostatin analog therapy. Significantly higher rates of Durable Response (DR, predefined as Bowel Movement (BM) frequency reduction ≥30% from baseline for ≥50% of the 12 week double blind period) were observed with TE (TE 250mg: 44%, TE 500mg: 42%) vs placebo (20%).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Cella D

Authors: Cella D, Beaumont J, Hudgens S, Marteau F, Feuilly M,

Keywords: telotristat ethyl, HRQoL, carcinoid syndrome,

#45 Neuroendocrine tumor disease state and RAND-36 health-related quality of life scores

Introduction: Health-related quality of life (HRQL) can be disrupted in patients with malignancies.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Phan A, Beaumont J, Liu Z, Choi S, Cella D,

Keywords: neuroendocrine tumor, health-related quality of life, carcinoid syndrome,

#44 Somatostatin analogue therapy and RAND-36 health-related quality of life scores in patients with neuroendocrine tumors

Introduction: Somatostatin analogues (SSAs) are used in patients with neuroendocrine tumors (NETs) for the management of carcinoid syndrome and/or delay of disease progression.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Yao J, Beaumont J, Choi S, Cella D, Liu Z,

Keywords: neuroendocrine tumor, health-related quality of life, somatostatin analogue, carcinoid syndrome,

#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores

Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Yao J

Authors: Beaumont J, Liu Z, Choi S, Yao J, Phan A,

Keywords: neuroendocrine tumor, health-related quality of life, diarrhea, flushing,